JAK3 inhibition: what potential for the future?

Area of Science:

• Immunology
• Pharmacology
• Transplantation Medicine

Background:

• Janus kinase 3 (JAK3) plays a crucial role in immune cell signaling.
• JAK3 inhibition demonstrates immunosuppressive effects across various preclinical models and in humans.
• STAT5 activation is a key downstream pathway affected by JAK3 inhibition, particularly in T-cells.

Purpose of the Study:

• To evaluate the efficacy and safety of CP-690,550 in preventing acute rejection in human kidney transplant recipients.
• To compare the effects of CP-690,550 versus calcineurin inhibitors on kidney function and histology.
• To identify the incidence of adverse events associated with CP-690,550 use in this patient population.

Main Methods:

• CP-690,550 was administered to low to moderate risk kidney transplant recipients.
• The study involved a combination therapy including mycophenolate mofetil, steroids, and basiliximab induction.
• Efficacy was assessed by prevention of acute rejection, and safety by monitoring overimmunosuppression consequences.

Main Results:

• CP-690,550 demonstrated comparable efficacy to calcineurin inhibitors in preventing acute kidney transplant rejection.
• The drug showed superior preservation of kidney function and histology compared to calcineurin inhibitors.
• An increased incidence of cytomegalovirus, BK virus infections, and lymphoproliferation was observed.

Conclusions:

• CP-690,550 offers a potential alternative to calcineurin inhibitors in kidney transplantation due to its efficacy and organ-sparing properties.
• The heightened risk of severe infections and lymphoproliferation due to overimmunosuppression necessitates careful risk-benefit assessment.
• These safety concerns ultimately led to the discontinuation of CP-690,550 development for kidney transplantation.